Usana Health Sciences Inc: Form 10-K for the period ended Dec 31, 2022
Filed with the SEC on Feb 28, 2023 and accepted by EDGAR at Feb 28, 2023, 19:34 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2022-01-02 to 2022-12-31 | $998.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2022-01-02 to 2022-12-31 | $193.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2022-01-02 to 2022-12-31 | $804.7m | us-gaap:GrossProfit |
| Research and development | 12 months2022-01-02 to 2022-12-31 | $11.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2022-01-02 to 2022-12-31 | $262.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2022-01-02 to 2022-12-31 | $107.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2022-01-02 to 2022-12-31 | $192.0k | us-gaap:InterestExpense |
| Income tax | 12 months2022-01-02 to 2022-12-31 | $39.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2022-01-02 to 2022-12-31 | $69.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-01-02 to 2022-12-31 | $3.59 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-01-02 to 2022-12-31 | $3.60 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-01-02 to 2022-12-31 | 19,310,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-02 to 2022-12-31 | $103.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-02 to 2022-12-31 | $10.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2022-01-02 to 2022-12-31 | $25.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-12-31 | $288.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $384.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $596.5m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $143.8m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2022-12-31 | $434.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000896264-23-000004. Last ingested by Listed: Oct 24, 2026, 14:59 ET. Listed shows no prices and gives no investment advice.